Davis Krista's Form 4 filing
Ani Pharmaceuticals Inc (ANIP) · filed Feb 23, 2026
- Accession no.
- 0001946439-26-000006
- Filed
- Feb 23, 2026
- Trade date
- Feb 19-20, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $296.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Davis KristaCIK 0001946439 | Officer (SVP, CHIEF HR OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 19, 2026 | Common Stock | SSaleDisposed | −2,084 | $77.53 | −$161,572.52 | 50,993 | Direct | |
| Feb 20, 2026 | Common Stock | SSaleDisposed | −1,730 | $77.99F2 | −$134,922.7 | 49,263 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The shares were sold in multiple trades at prices ranging from $77.45 to $78.58. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.